Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 59

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 59
---
, 3.6%49,881 706,403 261,270 1,166,510 Other advanced clinical stage programs975,489 398,633 1,466,051 845,304 Phase 1 and Phase 1-ready clinical stage programs628,595 204,894 1,125,342 434,443 Preclinical stage programs1,718,320 1,306,514 2,767,058 2,678,222 Other development programs— 10,132 — 22,926 Contra-R&D expenses(3,780,794)(1,991,167)(6,399,167)(4,647,358)Total research and development direct program costs907,863 3,614,895 2,032,655 5,663,405 Indirect costs:Personnel-related (including stock compensation)1,209,437 1,482,550 2,701,684 2,965,149 Other indirect costs70,462 81,978 199,196 160,177 Contra R&D expenses(759,000)(245,649)(1,207,392)(501,437)Total research and development indirect costs520,899 1,318,879 1,693,488 2,623,889 General and administrative2,377,866 2,448,130 4,687,030 5,118,711 Other operating expenses— — — 7,674 Total segment operating expenses3,806,628 7,381,904 8,413,173 13,413,679 Loss from operations(3,827,800)(7,359,466)(8,408,918)(13,381,939)Sale of royalty and milestone rights, net— 20,379,376 — 20,379,376 Interest expense268,533 217,902 402,583 427,040 Interest income(69,848)(145,633)(226,469)(233,766)Other income (expense), net10,002 (36,985)(190,242)648,863 Net (loss) income$(4,016,483)$12,910,656 $(8,394,790)$6,155,300 

27

13.    SUBSEQUENT EVENTS

Nasdaq Compliance